drug_type
RELEVANT_DRUG
intervention_type
Biological (therapeutic vaccine/immunotherapy)
drug_description
Therapeutic EBV-directed immunotherapy (intradermal/subcutaneous) designed to elicit or boost EBV-specific cytotoxic T-cell responses against EBV antigens on infected lymphocytes.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Epstein-Barr Virus Vaccines
drug_category
PEPTIDE VACCINE
drug_class
Vaccine
drug_delivery_route
Intradermal, Subcutaneous
drug_mechanism_of_action
Intradermal/subcutaneous administration of EBV antigenic peptides is taken up by antigen‑presenting cells and presented on MHC I/II, priming and boosting EBV‑specific CD8+ and CD4+ T‑cell responses that recognize EBV antigens on infected lymphocytes, leading to targeted cytotoxic killing of EBV‑infected cells.
drug_name
EBV immunological agent
nct_id_drug_ref
NCT06666153